Use of QTRAC Technique to Measure Axonal Excitability in Anti-MAG Neuropathy

• Register: ClinicalTrials.gov
• Last refreshed on: 20 February 2023
• Main ID: NCT02468596
• Date of registration: 03/03/2015
• Prospective Registration: No
• Primary sponsor: Fondation Ophtalmologique Adolphe de Rothschild
• Public title: Use of QTRAC Technique to Measure Axonal Excitability in Anti-MAG Neuropathy EXCIMAG
• Scientific title: Axonal Excitability Measured by QTRAC Technique in Patients With Anti-MAG Neuropathy
• Date of first enrolment: November 2014
• Target sample size: 6
• Recruitment status: Terminated
• URL: https://clinicaltrials.gov/show/NCT02468596
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

France

Key inclusion & exclusion criteria

Inclusion Criteria:

- Anti-MAG neuropathy (peripheral neuropathy and IgM monoclonal gammopathy with anti-MAG
activity superior to 1000 BTU)

Exclusion Criteria:

- current treatment with a medication that modifies peripheral nerve excitability (e.g.
anticonvulsivants)



Age minimum: 18 Years
Age maximum: 90 Years
Gender: All

Health Condition(s) or Problem(s) studied

Peripheral Neuropathy Associated With Anti-myelin Associated Glycoprotein Antibodies (Anti-MAG Neuropathy)

Intervention(s)

Other: QTRAC assessment

Other: Clinical assessment of peripheral nerve function

Primary Outcome(s)

QTRAC-measured refractority of the median nerve [Time Frame: Inclusion]

Secondary ID(s)

AGN_2014-20

Source(s) of Monetary Support

Please refer to primary and secondary sponsors